Skip to main content
. 2015 Jun 13;6(5-6):247–253. doi: 10.1007/s12672-015-0228-z

Table 3.

Treatment and outcomes of patients with thymic carcinoid (TC) tumors

Case Extent of disease at diagnosis Therapy Recurrence Follow-up (years) Death
1 Local extension with tumor in entire anterior mediastinum and pleural cavities SR + RT Residual tumor with local progression 3 Yes, due to TC
2 No local extension or distal metastasis SR at diagnosis; at time of recurrence 5-FU + RT + somatostatin analog At 6 years postoperatively, anterior mediastinal mass with pericardial effusion; at 8 years, metastatic disease to sacrum and ribs 10 Yes, unknown cause
3 No local extension or distant metastasisa SR; brain resection of metastatic lesion + WBRT 4200 At 4 years postoperatively with bone and brain metastases 4 Yes, due to TC
4 No local extension or distant metastasis SR Local recurrence at 11 years postoperatively 11 No
5 Local extension with positive surgical margins, vascular and lymph node invasion SR At 6 years postoperatively brain metastases and at 7 years lung metastases 8 Yes, due to TC
6 No local extension or distant metastasis SR No 5 No
7 Local extension with positive surgical margins Cisplatin + etoposide followed by SR and RT; at time of recurrence started on tyrosine kinase inhibitor At 3.5 years postoperatively, mediastinal and lung nodules 3 No

SR surgical resection, RT radiation therapy, 5FU 5 fluorouracil, WBRT whole brain radiation therapy

aScreening chest roentgenogram showed a mediastinal mass that was resected and reported as a benign thymic tumor. Four years later, the patient presented with neurologic symptoms and metastatic disease to the brain was diagnosed